Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

Boehringer Ingelheim and CarthroniX announce partnership

Boehringer Ingelheim and CarthroniX have announced a partnership to pursue small molecule therapeutics in canine oncology, this will focus on identifying new molecules to target cancers in dogs

Boehringer Ingelheim, a global leader in animal health, and CarthroniX, a biopharmaceutical company focused on developing small molecule-based therapies for degenerative and aging-related diseases, announce that they have entered into a research collaboration to pursue small molecule therapeutics in canine oncology.

When it comes to the treatment of cancer in dogs, veterinarians have limited therapeutic options compared to other areas. Due to this unmet medical need, Boehringer Ingelheim is committed to oncology research in animal health. Under the agreement, Boehringer Ingelheim will test a select group of small molecules provided by CarthroniX with the goal of determining their impact on canine cancers. 

“Cancer is the leading disease-related cause of death in dogs. Current therapies to treat cancer in dogs are often non-specific and sometimes have significant side effects. Therefore, we are searching for new potential therapeutic options to support veterinarians in their care of animals,” says Dr Marlene Hauck, head of oncology research at Boehringer Ingelheim Animal Health. “The impressive work of CarthroniX in developing small molecules could potentially be an effective way to treat cancer.”

“We are thrilled to combine our unique molecules with the expertise and reach of the Animal Health division of Boehringer Ingelheim. We see the potential to define a new paradigm in treating canine cancers and thus have major impacts on animal health,” says Hassan Serhan, PhD, CEO of CarthroniX.

Have you heard about our
Membership?

The number one resource for veterinary professionals.

From hundreds of CPD courses to clinical skills videos. There is something for everyone.

Discover more